A Real-World Analysis of the Population with Hepatitis C Virus Infection Affected by Type 2 Diabetes in Italy: Patients’ Characteristics, Comorbidity Profiles and Treatment Patterns
Edoardo Giovanni Giannini,
Alessandra Mangia,
Filomena Morisco,
Pierluigi Toniutto,
Angelo Avogaro,
Stefano Fagiuoli,
Claudio Borghi,
Francesca Frigerio,
Marta Nugnes,
Chiara Veronesi,
Maria Cappuccilli,
Margherita Andretta,
Marcello Bacca,
Antonella Barbieri,
Fausto Bartolini,
Gianmarco Chinellato,
Andrea Ciaccia,
Renato Lombardi,
Daniela Mancini,
Romina Pagliaro,
Loredana Ubertazzo,
Luca Degli Esposti,
Francesca Romana Ponziani
Affiliations
Edoardo Giovanni Giannini
Gastroenterology Unit, Department of Internal Medicine, University of Genoa, 16126 Genoa, Italy
Alessandra Mangia
Liver Unit, Department of Medical Sciences, Fondazione “Casa Sollievo della Sofferenza” IRCCS, 71013 San Giovanni Rotondo, Italy
Filomena Morisco
Gastroenterology Unit, Department of Clinical Medicine and Surgery, University of Naples “Federico II”, 80138 Naples, Italy
Pierluigi Toniutto
Hepatology and Liver Transplantation Unit, University of Udine, 33100 Udine, Italy
Angelo Avogaro
Department of Medicine, Section of Diabetes and Metabolic Diseases, University of Padova, 35128 Padua, Italy
Stefano Fagiuoli
Gastroenterology Hepatology and Transplantation Unit, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy
Claudio Borghi
Department of Medical and Surgical Sciences, IRCCS AOU S. Orsola di Bologna, 40138 Bologna, Italy
Background and Objectives: HCV infection represents a main risk factor for type 2 diabetes (T2D). This real-world analysis investigated the HCV-positive (HCV+) population with a T2D co-diagnosis in Italy. Methods: From 2017 to 2021, HCV+ patients were identified from administrative databases and stratified into T2D-HCV+ and HCV+-only cohorts in the presence/absence of a T2D diagnosis. Both cohorts were further divided by treatment with direct-acting antivirals (DAAs). The subgroups were compared for demographic variables, comorbidity profiles, most frequent hospitalizations, and drug prescriptions before inclusion. A sensitivity analysis was performed on patients included after 2019, the year of widespread use of pangenotypic DAAs. Results: Considering HCV+ patients aged ≥55 years, T2D-HCV+ patients (N = 1277) were significantly (p p p Conclusions: The co-presence of T2D in HCV+ patients resulted in a worse clinical status, as confirmed by the more frequent requirement of hospitalizations and complex polypharmacy regimens.
